GamaMabs Pharma develops innovative monoclonal antibodies targeting cancer, led by CEO Stéphane Degove. Its lead candidate, GM102 (formerly 3C23K), targets the Anti‑Mullerian Human Receptor II (AMHRII/MISRII) in gynecological cancers and is in pre‑IMPD stage. The company planned first‑in‑man clinical trials of GM102 in the first half of 2016. GamaMabs intends to use the proceeds from its Series B to conduct the phase I and phase II clinical trials of GM102. The company previously raised €3.6m in a 2013 Series A led by InnoBio (Bpifrance). GamaMabs Pharma was launched to develop new cancer therapies and its lead product is a monoclonal antibody, 3C23K, targeting gynecological cancers including ovarian cancer. The company holds an exclusive global sublicense from the LFB group for 3C23K and is supported by LFB’s EMABling® platform. 3C23K has shown effectiveness in experimental models of ovarian cancer and the program is developed in collaboration with Inserm, Université de Montpellier and the Institut du cancer de Montpellier. Management includes Dr Jean-François Prost (VP R&D and Strategy) and Stéphane Degove (CEO). The financing will be used to validate the therapeutic concept and to prepare the company’s first clinical trial, with an aim to launch clinical trials in 2015. LFB also provides bioproduction capacity through its subsidiary LFB Biomanufacturing and holds a minor equity participation in GamaMabs Pharma.

Total raised

$21M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2015